Immutep (NASDAQ:IMMP) Stock Passes Below Fifty Day Moving Average – Time to Sell?

Shares of Immutep Limited (NASDAQ:IMMP) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.92 and traded as low as $1.88. Immutep shares last traded at $1.88, with a volume of 56,504 shares trading hands.

Immutep Stock Performance

The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average of $1.92 and a 200-day moving average of $2.04.

Institutional Investors Weigh In On Immutep

Institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new position in shares of Immutep during the 4th quarter worth $74,000. OLD Mission Capital LLC purchased a new position in shares of Immutep during the 4th quarter worth $36,000. ABC Arbitrage SA purchased a new position in shares of Immutep during the 4th quarter worth $152,000. XY Capital Ltd lifted its stake in shares of Immutep by 52.0% during the 4th quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company’s stock worth $357,000 after purchasing an additional 56,306 shares during the period. Finally, Fortitude Advisory Group L.L.C. purchased a new position in shares of Immutep during the 4th quarter worth $28,000. Hedge funds and other institutional investors own 2.32% of the company’s stock.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.